97307 ⎘
Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
METHODS AND MATERIALS FOR TREATING CANCER
#1502P329G ANTIBODY TARGETING BCMA, COMBINATION OF SAME WITH CHIMERIC ANTIGEN RECEPTOR CELL, AND USE THEREOF
#1503TRANSMEMBRANE NEOANTIGENIC PEPTIDES
#1504METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES
#1505METHOD FOR PREVENTING AND/OR TREATING THROMBOEMBOLIC DISEASES
#1506ANTI-GLYCAN ANTIBODIES AND USES THEREOF
#1507ANTI-TROP-2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
#1508PROTEASE-CLEAVABLE MASKED ANTIBODIES
#1509ANTI-CD40 ANTIBODIES AND USES THEREOF
#1510COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES
#1511AGONISTIC LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES COMPRISING THEM
#1512ANTIBODY BINDING TO BCMA AND USE THEREOF
#1513ANTI-CD-25 ANTIBODY
#1514CCR8 ANTIGEN BINDING UNIT AND USES THEREOF
#1515FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS
#1516ANTI-PD-1 ANTIBODIES AND USES THEREOF
#1517PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF
#1518MANABODIES TARGETING P53 TUMOR ANTIGENS AND METHODS OF USING
#1519ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES
#1520ANTI-CD33 ANTIBODIES AND USES THEREOF
#1521SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
#1522MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3
#1523IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
#1524IL-18 BINDING MOLECULES
#1525ANTI-TAUC3 ANTIBODIES AND USES THEREOF
#1526ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF
#1527IL-10 Monomer Fusion Protein and Use thereof
#1528Anti-DXd Antibodies and Methods of Use
#1529ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF
#1530ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
#1531MULTIFUNCTIONAL IMMUNE CELL THERAPIES
#1532BISPECIFIC ANTIBODY AGAINST CD40 AND CLDN18.2 AND APPLICATION THEREOF
#1533MODIFIED PROTEIN OR POLYPEPTIDE
#1534BISPECIFIC ANTIBODIES TARGETING CD137 AND USES THEREOF FOR ANTI-CANCER IMMUNOTHERAPY
#1535ANTI-HLA-G ANTIBODIES
#1536ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
#1537FELINE ANTIBODY VARIANTS
#1538Binding agents and methods of using the same
#1539Anti-SIRP-Beta1 Antibodies and Methods of Use Thereof
#1540BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS
#1541ANTI-TGF-BETA ANTIBODIES AND THEIR USE
#1542ANTI-TGFbeta ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF
#1543ANTI-RSV ANTIBODY AND APPLICATION THEREOF
#1544POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
#1545ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
#1546IMMUNOGLOBULINS AND USES THEREOF
#1547IgE binding proteins and uses thereof
#1548ANTIBODIES THAT SPECIFICALLY BIND TO API5 PROTEIN
#1549HER3 ANTIGEN-BINDING MOLECULES
#1550PROTEINS COMPRISING CD20 BINDING DOMAINS, AND USES THEREOF
#1551ANTI-TNFR2 ANTIBODIES AND USES THEREOF
#1552IL2RB/IL2G SYNTHETIC CYTOKINES
#1553ANTI-CCR8 ANTIBODIES AND USES THEREOF
#1554BISPECIFIC AGONISTIC ANTIBODIES TO IL12 RECEPTOR
#1555ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
#1556ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF
#1557BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF
#1558IMMUNOMODULATORY TRISPECIFIC T CELL ENGAGER FUSION PROTEINS
#1559ANTI-IDIOTYPE ANTIBODIES
#1560Optimized CD3 Antigen Binding Domains
#1561Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof
#1562METHODS, COMPOSITIONS, AND KITS FOR MODIFYING IMMUNE CELL ACTIVITY VIA KIR2DL5
#1563CELL-BINDING PROTEINS AND METHODS OF USE
#1564RESISTIN-SPECIFIC ANTIBODY AND USE THEREOF
#1565Methods for Producing Anti-TNF Antibody Compositions
#1566ANTI-GRP78 ANTIBODIES AND THEIR USES
#1567TRANSTHYRETIN (TTR) MONOMER BINDING ANTIBODIES
#1568VHH ANTIBODIES AGAINST SARS-COV-2 VARIANTS
#1569APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#1570APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#1571ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
#1572SURVIVIN TARGETING POLYPEPTIDES FOR DETECTION AND TREATMENT OF CANCER
#1573SAFETY CONTROL OF SWITCHABLE CHIMERIC ANTIGEN RECEPTOR T CELLS USING DOSE-ADJUSTABLE ADAPTORS
#1574AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR)
#1575MECHANISM OF ACTION
#1576ANTI-IgE ANTIBODIES
#1577ANTIBODIES AND METHODS OF USE
#1578Procoagulant Antibodies
#1579ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS
#1580HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#1581ANTIBODIES AGAINST CD14 AND USES THEREOF
#1582ANTIBODIES AND USES THEREOF
#1583ANTIBODIES SPECIFICALLY RECOGNIZING TNFR2 AND USES THEREOF
#1584BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#1585ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES
#1586ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODIES
#1587MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
#1588Antibody Binding to Tie2 and Use Thereof
#1589WNT SIGNALING AGONIST MOLECULES
#1590NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
#1591FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED COMPLEMENT BINDING
#1592ANTI-CANINE PD-L1 ANTIBODIES
#1593ENGINEERED FC VARIANTS
#1594Engineered Antibodies
#1595SIGLEC-6 ANTIBODIES, DERIVATIVE COMPOUNDS AND RELATED USES
#1596ANTIBODY AGAINST HUMAN TIGIT AND USE THEREOF
#1597PROTEINS THAT BIND SP17 INCLUDING FULLY-HUMAN ANTI-SP17 ANTIBODIES
#1598ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF
#1599CANCER SPECIFIC PLECTIN-1 SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
#1600Anti-SOST Antibody Pharmaceutical Composition and Use Thereof
#1601ANTI-NGF ANTIBODIES AND USES THEREOF
#1602NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE
#1603MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2
#1604HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
#1605ANTI-KLK5 ANTIBODIES AND METHODS OF USE
#1606BISPECIFIC ANTIBODY AND USE THEREOF
#1607ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE
#1608Humanized complement 5A receptor 1 antibodies and methods of use thereof
#1609MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2
#1610BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF
#1611NEUTRALIZING ANTI-CD95L MONOCLONAL ANTIBODIES
#1612ANTI-CD122 ANTIBODIES, ANTI-CD132 ANTIBODIES, AND RELATED BISPECIFIC BINDING PROTEINS
#1613NOVEL ANTI-IL-36R ANTIBODIES
#1614PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY
#1615DUAL MHC-TARGETING T CELL ENGAGER
#1616ACTIVATABLE BISPECIFIC ANTI-CD47 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#1617HUMAN CD276-TARGETING MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#1618CLAUDIN 18.2-BINDING ANTIBODIES AND FRAGMENTS THEREOF
#1619ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
#1620ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF
#1621ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF
#1622POLYNUCLEOTIDE, EXPRESSION CASSETTE, VECTOR, HOST CELL, POLYPEPTIDE, PHARMACEUTICAL COMPOSITION, USE OF A POLYPEPTIDE, METHOD FOR PRODUCING A POLYPEPTIDE, AND METHOD FOR PREVENTING OR TREATING INFECTIONS CAUSED BY FLAVIVIRUSES
#1623HIV-BINDING PEPTIDES AND MEDICAL USE THEREOF
#1624MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
#1625MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#1626A GPC3-targeting antibody-interferon a fusion protein and a use thereof
#1627METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#1628BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#1629ANTI-ADAMTS13 ANTIBODY AND USE THEREOF
#1630PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF
#1631IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER
#1632ANTI-IL-11RA ANTIBODIES
#1633TrkA ANTIBODY AND APPLICATION THEREOF
#1634ANTI-VEGFR1 ANTIBODIES AND THEIR USES
#1635COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
#1636TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES
#1637TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES
#1638NOVEL PD-1 BINDING DOMAINS
#1639NOVEL PD-1 BINDING DOMAINS
#1640MULTISPECIFIC ANTIBODIES AND USES THEREOF
#1641CYTOTOXICITY-INDUCING THERAPEUTIC AGENT FOR USE IN TREATMENT OF CANCER
#1642ANTI-TIGIT CONSTRUCTS AND USES THEREOF
#1643PILRA ANTIBODIES AND METHODS OF USE THEREOF
#1644ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#1645MECHANICALLY INTERLOCKING COMPLEXES
#1646IL-7 Binding Proteins and Their Use in Medical Therapy
#1647Anti-IL-33 Antibodies and Uses Thereof
#1648PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA
#1649ANTIBODIES AND METHODS OF USING THEREOF
#1650GLYCOPROTEIN A REPETITIONS PREDOMINANT (GARP)-BINDING ANTIBODIES AND USES THEREOF
#1651ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF
#1652Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof
#1653NEW INTERLEUKIN-7 IMMUNOCONJUGATES
#1654Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon Receptors
#1655HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF
#1656ANTIGEN BINDING RECEPTORS
#1657Methods for Inhibiting Fibrosis in a Subject in Need Thereof
#1658Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor
#1659uPAR Binding Compositions and Uses Therefor
#1660SINGLE-DOMAIN 4-1BB ANTIBODIES
#1661ANTI-IL 18BP ANTIBODIES
#1662ANTIBODY CONJUGATES FOR THE TREATMENT OF CANCER
#1663COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
#1664BISPECIFIC CD16A BINDERS
#1665CD3-TARGETING T-CELL ENGAGERS WITH IMPROVED THERAPEUTIC INDEX
#1666Trispecific Engineered Antibodies
#1667COMPOSITIONS COMPRISING ANTIGEN-BINDING MOLECULES
#1668ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
#1669MONOCLONAL ANTIBODY TARGETING TIGIT
#1670HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
#1671ANTIBODIES DIRECTED AGAINST ALPHA-FOLATE RECEPTOR
#1672BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
#1673METHODS OF ISOLATING ALLERGEN-SPECIFIC ANTIBODIES FROM HUMANS AND USES THEREOF
#1674IL-2 FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#1675HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
#1676SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN
#1677CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE
#1678Bispecific Binding Molecule
#1679PROTEIN-BASED CONJUGATION CARRIERS
#1680MOLECULES THAT BIND TO CD94/NKG2A HETERODIMER POLYPEPTIDES
#1681ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
#1682ANTIBODY MASKS AND USES THEREOF
#1683Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
#1684ACE2-Targeted Compositions and Methods for Treating COVID-19
#1685ANTI-OX40 ANTIBODIES AND METHODS OF USE
#1686DR5-TARGETING MULTABODIES FOR THE TREATMENT OF CANCER
#1687METHODS AND COMPOSITIONS FOR INCREASING N-ACETYLGLUCOSAMINIDASE ACTIVITY IN THE CNS
#1688ANTI IL-36R ANTIBODIES
#1689BISPECIFIC BINDING PROTEINS AGAINST ALARMINS AND USES THEREOF
#1690Binding Molecules Targeting IL-2 Receptor
#1691ANTI-ILT4 AND ANTI-PD-1 BISPECIFIC CONSTRUCTS
#1692SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES
#1693ANTI-CD8 ANTIBODIES AND USES THEREOF
#1694MULTISPECIFIC ANTIBODIES AND USES THEREOF
#1695CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
#1696HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF
#1697ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES
#1698ANTI-CLDN18.2 ANTIBODY AND USE THEREOF
#1699ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF
#1700ENGINEERED DUAL BINDING ANTIBODIES AND USES THEREOF
#1701STABILIZED TCR CONSTRUCTS AND METHODS OF USE
#1702Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1703FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF
#1704Combined Immunoassay and Magnetic Immunoassay Methods for Extended Range of Sensitivity
#1705ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
#1706MATERIALS FOR VALUABLE METAL RECOVERY
#1707MOLECULES THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) POLYPEPTIDES
#1708MULTISPECIFIC ANTIBODIES AND USES THEREOF
#1709A PLATFORM TO OBTAIN MONOCLONAL ANTIBODIES DIRECTED AGAINST PROCESSED TUMOR-SPECIFIC ANTIGENS
#1710CD38 MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#1711Variant nucleic acid libraries for coronavirus
#1712MUTATIONS IN FELINE ANTIBODY CONSTANT REGIONS
#1713OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
#1714ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
#1715ANTI-AMHRII ANTIBODIES
#1716CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS
#1717ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION
#1718HUMANIZED ANTI-EGFR VIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
#1719DRUG FORMULATION OF ANTI-HLA-DQ2.5 ANTIBODY
#1720CELIAC DISEASE EPITOPES
#1721ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF
#1722NOVEL ANTI-CD276 ANTIBODIES AND THE USES THEREOF
#1723ANTI-CD3 ANTIBODIES AND USES THEREOF
#1724METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY
#1725FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF AND APPLICATION THEREOF
#1726SIRP GAMMA ANTIBODIES AND USES THEREOF
#1727ANTI-CD19 ANTIBODIES AND USES THEROF
#1728ANTIBODY CONSTRUCTS FOR MSLN AND CD3
#1729NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST L-THYROXINE AND DIAGNOSTIC USES THEREOF
#1730MONOCONAL ANTIBODIES TO IL-25 AND USES THEREOF
#1731ANTI-IL23 ANTIBODY FUSION PROTEIN AND USES THEREOF
#1732METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS
#1733CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE
#1734Anti-PfRH5 Antibodies and Antigen-Binding Fragments Thereof
#1735COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#1736COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#1737COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#1738ANTIBODIES TARGETING C5AR
#1739ANTIGEN-BINDING MOLECULES THAT BIND TO PORPHYROMONAS GINGIVALIS
#1740ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF I
#1741ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION IN PEDIATRIC SUBJECTS
#1742April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
#1743PARTIAL AGONISTS OF INTERLEUKIN-2, NUCLEIC ACIDS ENCODING THE SAME, AND METHODS OF USE THEREOF
#1744COMPOSITIONS AND METHODS FOR THE TREATMENT OF P53-MEDIATED CANCERS
#1745ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF
#1746Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1747Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#1748DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#1749Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#1750HER2 VARIANT CAR
#1751ANTI-LAG3 BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
#1752Humanized complement 5a receptor 1 antibodies and methods of use thereof
#1753ANTI-TNFR2 MONOCLONAL ANTIBODY AND APPLICATION THEREOF
#1754ANTI-CD30 ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR COMPRISING THEREOF
#1755ANTIGEN-BINDING MOLECULE
#1756IL1RAP ANTIBODIES AND USES THEREOF
#1757Antibodies Directed to TIE-2 and Methods of Use
#1758IMMUNOTHERAPY TARGETING TUMOR NEOANTIGENIC PEPTIDES
#1759LILRB2-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
#1760METHODS OF TREATING CANCERS ASSOCIATED WITH IMMUNOSUPPRESSIVE B CELLS
#1761TREATMENT WITH ANTI-KIR3DL2 AGENTS
#1762ANTI-TIM-3 ANTIGEN ANTIBODY OR ANTIBODY DERIVATIVE, AND USE THEREOF
#1763ANTI-GROWTH HORMONE ANTIBODY
#1764BI-FUNCTIONAL FUSION PROTEIN AND USES THEREOF
#1765METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES
#1766HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
#1767ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE
#1768ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION
#1769NOVEL ANTIBODY SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS
#1770ANTI-EPHA4 ANTIBODY
#1771IMMUNOMODULATING TRANSGENIC PLANTS AND RELATED METHODS
#1772ANTIBODIES WITH MODULATED GLYCAN PROFILES
#1773CD20 AND CD22 TARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES
#1774ANTI-NGLY-1 ANTIBODIES AND METHODS OF USE
#1775Anti-Jagged1 Antibodies and Methods of Use
#1776CD5L-BINDING ANTIBODIES AND USES FOR THE SAME
#1777ANTI-OX40 ANTIBODIES, MULTISPECIFIC ANTIBODIES AND METHODS OF USE
#1778ANTI-4-1BB NANOBODIES
#1779MODIFIED ANTI-VEGFR2 (KDR) ANTIBODY AND USE THEREOF
#1780ANTIBODIES BINDING TO HLA-A2/MAGE-A4
#1781HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
#1782Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof
#1783Anti-DLL3 Antibodies and Uses Thereof
#1784ANTIBODY SPECIFICALLY BINDING TO STREP-TAG II TAG AND USE THEREOF
#1785HUMANIZED ANTIBODY INHIBITORS FOR CATHEPSIN S
#1786FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
#1787MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#1788ASSAY METHOD FOR RELAXIN
#1789COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS
#1790ANTIBODIES AGAINST CLEAVED CDCP1 AND USES THEREOF
#1791ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
#1792CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS
#1793DUPLEXBODIES
#1794D3-BINDING MOLECULES AND USES THEREOF
#1795NOVEL DYSFUNCTIONAL P2X7 BINDERS
#1796ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F
#1797HUMANIZED ANTI-C5A ANTIBODIES AND USES THEREOF
#1798Tetanus prophylaxis
#1799IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION
#1800FULLY HUMAN SINGLE DOMAIN ANTIBODY-BASED ANTI-SARS-COV-2 BISPECIFIC NEUTRALIZING ANTIBODY AND USE THEREOF